Cancer groups say Trump administration’s drug pricing rule will likely harm patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

On the way out, the Trump administration has finalized a rule that uses international reference prices to lower Medicare Part B prices.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Paul Goldberg
Editor & Publisher

Login